VolitionRx Ltd (NYSEMKTS:VNRX), the cancer test specialist, has entered into a groundbreaking sales and distribution partnership with a rival life sciences group Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology starting in June.
These research-use-only kits are based on VolitionRx’s technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid- an indication that disease is present.
Once they are distributed with the help of Active Motif, these RUO kits will provide researchers with new ways to explore changes in gene expression across different diseases from clinical samples.
The RUO kits are based on the same Nu.Q immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.
“This is a fantastic opportunity for Volition and we expect that it will provide an additional revenue stream beyond that from the expected commercialization of our blood-based tests for cancer,” said Cameron Reynolds, Volition’s chief executive officer, in a press release.
VolitionRx’s cancer-screening tools have become quite popular, particularly in the area of colorectal cancer.
In the US, Volition is taking part in what is believed to be the largest ever colorectal cancer screening study in collaboration with the National Cancer Institute's Early Detection Research Network with a cohort of over 13,500 subjects.
Collection is underway and is expected to be completed in 2020. The idea is to build on the European studies to refine test performance and to present final data to the FDA before the study is completed.